



Capital increase is a success:

€ 17.3 million raised to underpin Naturex's expansion

Extension clause exercised

Avignon – April 3, 2009 – Naturex is pleased to announce the success of its capital increase of February 5, 2009.

Participation amongst the Group's shareholders, whose preferential rights entitled them to subscribe to shares on a non-reducible basis at a rate of 1 new share for 4 old shares, proved particularly high at over 88%. Shares proposed on a reducible basis were oversubscribed 4.2 times, prompting Naturex's Board of Directors to exercise the extension clause in full.

All told, the operation raised a gross € 17.3 million via the issue of 866,863 new shares with a par value of € 20.

The funds raised reinforce Naturex's financial structure and, as a result, enable the Group to pursue its organic growth and finance future targeted acquisitions.

"We are delighted at the very strong response from our shareholders despite today's difficult financial climate and would like to thank them for this show of faith. Thanks to the operation, Naturex is ideally placed to pursue its ambitious organic growth policy. It also has the extra room for maneuver it needs to take advantage of new opportunities in terms of acquisitions that will further cement our positioning", said Jacques Dikansky, Chairman and CEO of Naturex.

The new shares, which are eligible for dividends from January 1, 2008, will be issued on March 5, 2009 and traded under the same ISIN code as existing Naturex shares, namely FR0000054694.

Following the operation, Naturex's capital consists of 3,882,040 shares. SGD, the family-owned holding company headed up by Jacques Dikansky, and the Group's directors jointly hold 25.6% of the Group's capital.

The lead manager for the operation was CIC Vizille Capital Finance.

Naturex will publish its yearly results for 2008 on March 30, 2009 after the close of trading.

If you would like to receive financial information about Naturex by e-mail, register at:

www.actus-finance.com

Naturex has been listed on Euronext Paris, segment C since October 1996
ISIN FR0000054694 - Reuters NATU.LN - Bloomberg NRX:FP



About Naturex

NRX
LISTED
NYSE
EURONEXT.

Naturex manufactures and sells natural ingredients for the food, flavor, nutraceutical, cosmetic and pharmaceutical industries. Based in Avignon, France, the Group employs 570 members of staff and over 90% of its sales are generated outside of France. Naturex has industrial sites in France, Morocco, the United States and Italy, as well as subsidiaries in China and the United Kingdom and representative offices in Germany and Singapore. www.naturex.com

Naturex contacts:	Actus Finance contacts:
Jacques Dikansky, Chairman and CEO Tel : +33 (0)4 90 23 96 89 naturex@naturex.com	Laurence Marquézy, Investor Relations Tel : + 33 (0)1 72 74 82 23 lmarquozy@actus.fr
Thierry Lambert, Deputy Chief Executive Officer Tel : +33 (0)4 90 23 96 89 t.lambert@naturex.com	Anne Catherine Bonjour, Press Relations Tel : + 33 (0)1 53 67 36 93 acbonjour@actus.fr